FDA Panel Backs Broad Acute Coronary Syndromes Claim For Brilinta
Executive Summary
An FDA advisory committee's blessing of AstraZeneca's Brilinta clinical strategy should reassure other drug developers that a single pivotal trial encompassing the spectrum of acute coronary syndromes and treatment strategies can support a broad claim for reducing thrombotic events